Key Highlights
• Board increased from seven to eight directors, creating a vacancy filled by Dr. Nerissa Kreher.
• Initial equity award to Dr. Kreher valued at approximately $450,000, with annual grants of about $300,000.
• The company names a chairperson; Marla S. Persky designated lead independent director.
Xeris Biopharma Holdings Inc. (NASDAQ: XERS) announced a series of board and governance modifications effective July 1 2026. The changes include adding a new director, expanding the board, and redefining leadership roles to align with the company’s growth strategy.
Board Expansion
The board voted on June 29 2026 to raise its size from seven to eight members, opening a seat that was promptly filled by Dr. Nerissa Kreher. The addition brings fresh clinical expertise to Xeris Biopharma’s oversight body.
New Director Profile
Dr. Kreher joins as a Class III director, with a term set to conclude at the 2027 annual shareholders’ meeting. She brings a record of senior medical leadership, most recently serving as chief medical officer at Alltrna and as founder of Mountainview Clinical Development Consulting.
Compensation Package
In line with the company’s non‑employee director compensation plan, Dr. Kreher received an initial equity award whose grant‑date fair value totals approximately $450,000. Starting with the 2027 meeting, she will be eligible for an annual equity grant valued at roughly $300,000. Both awards vest in installments subject to continued board service.
Leadership Restructure
The board also appointed a chairperson to oversee board activities, while maintaining independent oversight through the appointment of Marla S. Persky as lead independent director. This arrangement is intended to balance executive insight with governance independence.
Governance and Indemnification
The board executed a standard indemnification agreement for Dr. Kreher, mirroring the firm’s existing director protection framework. The agreement confirms that Dr. Kreher will receive the same legal safeguards afforded to other non‑employee directors.
Shareholder Outlook
These governance adjustments aim to strengthen Xeris Biopharma’s strategic direction as it advances its pipeline of RNA‑based therapeutics. Investors will monitor how the enhanced board expertise and clarified leadership hierarchy influence upcoming clinical milestones and market performance.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...